{"hands_on_practices": [{"introduction": "To understand how the body plan is laid out, we must first grasp the molecular-level interactions that switch genes on and off. This practice delves into the thermodynamic principles governing how transcription factors like Hox proteins find and bind to DNA. Specifically, you will quantify the dramatic impact a cofactor can have on binding affinity, illustrating a fundamental mechanism for modulating gene expression by translating a change in binding energy, $\\Delta G$, into a fold-change in DNA occupancy [@problem_id:2644521].", "problem": "In vertebrate axial patterning, the transcriptional output of a cis-regulatory module responsive to Homeobox (Hox) transcription factors can be modeled by the equilibrium occupancy of a single Hox site. Consider a minimal thermodynamic model of binding in which the promoter has two states: unbound with reference free energy set to zero, and bound by a Hox–DNA complex with binding free energy $\\,\\Delta G\\,$. The probability of the bound state at equilibrium is given by Boltzmann weighting of microstates, with the bound state weight proportional to $\\exp(-\\Delta G/(R T))$ when the free transcription factor concentration is sufficiently low that the occupancy scales linearly with the Boltzmann factor. A Three Amino acid Loop Extension (TALE) cofactor such as PBX/Meis increases the effective binding affinity by lowering the binding free energy by $\\,\\Delta G_{\\mathrm{cof}}=-2\\,\\mathrm{kcal\\,mol^{-1}}\\,$ relative to the cofactor-free case, without changing the transcription factor concentration or other cellular parameters.\n\nUsing this equilibrium model and assuming the low-occupancy regime where the bound-state probability is proportional to $\\exp(-\\Delta G/(R T))$, compute the fold-change in occupancy, defined as $F = p_{\\mathrm{with\\ cofactor}}/p_{\\mathrm{without\\ cofactor}}$, at physiological temperature $T = 310\\,\\mathrm{K}$. Use the gas constant in energy units of kilocalories, $R = 1.9872 \\times 10^{-3}\\,\\mathrm{kcal\\,mol^{-1}\\,K^{-1}}$. Round your answer to three significant figures and report it as a dimensionless number (no units).", "solution": "The problem requires the calculation of the fold-change in the occupancy of a Hox transcription factor binding site upon the introduction of a cofactor. The problem is well-posed and grounded in the fundamental principles of statistical thermodynamics as applied to molecular biology. We shall proceed with a formal derivation.\n\nThe system is at thermodynamic equilibrium at a constant temperature $T$. According to the principles of statistical mechanics, the probability of a system being in a particular microstate $i$ with free energy $G_i$ is proportional to the Boltzmann factor, $\\exp(-G_i / (RT))$, where $R$ is the universal gas constant. The problem defines a simplified model with two states for the promoter: unbound and bound by a Hox protein. The free energy of the unbound state is set as the reference, $G_{\\text{unbound}} = 0$. The free energy of the bound state is defined by the free energy of binding, $\\Delta G$. Thus, the energy of the bound microstate is $G_{\\text{bound}} = \\Delta G$.\n\nThe problem states that we are in a low-occupancy regime, where the probability of the bound state, which we call the occupancy $p$, is directly proportional to the Boltzmann factor corresponding to the binding event. We can write this as:\n$$p = C \\exp\\left(-\\frac{\\Delta G}{RT}\\right)$$\nHere, $\\Delta G$ is the Gibbs free energy of binding, and $C$ is a proportionality constant that depends on factors held constant in this problem, such as the concentration of the transcription factor.\n\nWe must consider two scenarios. First, binding without the cofactor. Let the binding free energy in this case be $\\Delta G_1$. The occupancy, $p_{\\text{without cofactor}}$, is:\n$$p_{\\text{without cofactor}} = C \\exp\\left(-\\frac{\\Delta G_1}{RT}\\right)$$\n\nSecond, binding in the presence of the TALE cofactor. The cofactor alters the binding affinity. The problem states that the cofactor lowers the binding free energy by $\\Delta G_{\\mathrm{cof}} = -2\\,\\mathrm{kcal\\,mol^{-1}}$. This means the new binding free energy, $\\Delta G_2$, is related to the original binding energy $\\Delta G_1$ by:\n$$\\Delta G_2 = \\Delta G_1 + \\Delta G_{\\mathrm{cof}}$$\nA negative value for $\\Delta G_{\\mathrm{cof}}$ signifies that the binding is more favorable (stronger affinity) in the presence of the cofactor. The occupancy with the cofactor, $p_{\\text{with cofactor}}$, is therefore:\n$$p_{\\text{with cofactor}} = C \\exp\\left(-\\frac{\\Delta G_2}{RT}\\right) = C \\exp\\left(-\\frac{\\Delta G_1 + \\Delta G_{\\mathrm{cof}}}{RT}\\right)$$\n\nThe problem asks for the fold-change in occupancy, $F$, defined as the ratio $p_{\\text{with cofactor}} / p_{\\text{without cofactor}}$. We can now compute this ratio:\n$$F = \\frac{p_{\\text{with cofactor}}}{p_{\\text{without cofactor}}} = \\frac{C \\exp\\left(-\\frac{\\Delta G_1 + \\Delta G_{\\mathrm{cof}}}{RT}\\right)}{C \\exp\\left(-\\frac{\\Delta G_1}{RT}\\right)}$$\nThe proportionality constant $C$ cancels. Using the property of exponents $\\exp(a+b) = \\exp(a)\\exp(b)$, we simplify the expression:\n$$F = \\frac{\\exp\\left(-\\frac{\\Delta G_1}{RT}\\right) \\exp\\left(-\\frac{\\Delta G_{\\mathrm{cof}}}{RT}\\right)}{\\exp\\left(-\\frac{\\Delta G_1}{RT}\\right)}$$\n$$F = \\exp\\left(-\\frac{\\Delta G_{\\mathrm{cof}}}{RT}\\right)$$\nThis elegant result shows that the fold-change in occupancy depends only on the change in binding free energy introduced by the cofactor, and not on the initial binding affinity of the Hox protein itself.\n\nNow, we must substitute the given numerical values to find the final answer. The provided values are:\n$\\Delta G_{\\mathrm{cof}} = -2\\,\\mathrm{kcal\\,mol^{-1}}$\n$T = 310\\,\\mathrm{K}$\n$R = 1.9872 \\times 10^{-3}\\,\\mathrm{kcal\\,mol^{-1}\\,K^{-1}}$\n\nFirst, we calculate the product $RT$, which represents the characteristic thermal energy per mole at this temperature:\n$$RT = (1.9872 \\times 10^{-3}\\,\\mathrm{kcal\\,mol^{-1}\\,K^{-1}}) \\times (310\\,\\mathrm{K}) = 0.616032\\,\\mathrm{kcal\\,mol^{-1}}$$\nNext, we compute the dimensionless argument of the exponential function:\n$$-\\frac{\\Delta G_{\\mathrm{cof}}}{RT} = -\\frac{-2\\,\\mathrm{kcal\\,mol^{-1}}}{0.616032\\,\\mathrm{kcal\\,mol^{-1}}} = \\frac{2}{0.616032} \\approx 3.24657$$\nFinally, we calculate the fold-change $F$:\n$$F = \\exp(3.24657) \\approx 25.7001$$\nThe problem requires the answer to be rounded to three significant figures.\n$$F \\approx 25.7$$\nThis result indicates that the presence of the cofactor increases the probability of the Hox protein occupying its target site by a factor of approximately $25.7$ under the specified conditions.", "answer": "$$\\boxed{25.7}$$", "id": "2644521"}, {"introduction": "Building upon the principles of molecular binding, we now explore how these interactions establish sharp spatial domains of gene expression along the body axis. Developmental systems often use opposing gradients of activators and repressors to define precise boundaries. This exercise asks you to build a simple but powerful kinetic model to see how a gradient of a repressive microRNA can sculpt the expression pattern of a Hox gene, quantitatively determining the position of a future anatomical structure [@problem_id:2644510].", "problem": "In patterning of the vertebrate anterior–posterior axis, Homeobox (Hox) gene expression boundaries can be sharpened by posterior microRNA (miRNA) repression of Hox transcripts. Consider a one-dimensional tissue coordinate, with position $x \\ge 0$ measured anteriorward from a posterior source of a specific miRNA that targets a given Hox messenger RNA (mRNA). The miRNA concentration profile is experimentally well fit by an exponential,\n$$\nm(x) = m_{0} \\exp(-\\lambda x),\n$$\nwith $m_{0} > 0$ and $\\lambda > 0$. Assume the following for the target Hox mRNA concentration $M(x,t)$ at fixed position $x$:\n- Transcription produces mRNA at a position-independent rate $\\,\\alpha\\,$ (molecules per unit volume per unit time).\n- mRNA is lost by basal first-order decay at rate constant $\\,\\delta\\,$ (per unit time).\n- miRNA-mediated degradation follows mass-action bimolecular kinetics with rate constant $\\,\\gamma\\,$ (per concentration per unit time), giving a loss term proportional to $\\,m(x) M(x,t)$.\n\nAssume $m(x)$ is quasi-stationary on the timescale of mRNA turnover, $M$ does not diffuse appreciably relative to these turnover rates, and parameters are time-invariant. Using the Central Dogma of Molecular Biology and mass-action kinetics as the fundamental base, do the following:\n1) Derive the steady-state mRNA concentration $M^{*}(x)$ as a function of $x$, $\\alpha$, $\\delta$, $\\gamma$, $m_{0}$, and $\\lambda$.\n2) Developmental patterning is set by a translational threshold $T$ (a fixed positive concentration) such that positions with $M^{*}(x) \\ge T$ adopt an anterior identity. Under the parameter regime $\\,\\alpha/\\delta > T > \\alpha/(\\delta + \\gamma m_{0})\\,$, derive a closed-form expression for the anterior boundary position $x_{b}$ satisfying $M^{*}(x_{b}) = T$.\n\nProvide your final answer as a single analytic expression for $x_{b}$ in terms of $\\,\\alpha, \\delta, \\gamma, m_{0}, \\lambda,\\,$ and $T$. Do not include units in your final boxed answer. No numerical evaluation is required.", "solution": "The problem presented is a standard exercise in quantitative developmental biology, combining principles of chemical kinetics with the concept of morphogen gradients to explain spatial patterning. It is scientifically sound, well-posed, and contains all necessary information for a unique solution. I will proceed with the derivation.\n\nThe fundamental principle governing the concentration of the Hox messenger RNA, $M(x,t)$, at a fixed position $x$ is the law of mass action, which leads to a rate equation describing the balance of production and degradation processes. The problem states three processes:\n$1$. A position-independent transcription rate, $\\alpha$. This is a zero-order production term.\n$2$. A basal first-order decay process with rate constant $\\delta$. This contributes a loss term $-\\delta M(x,t)$.\n$3$. A miRNA-mediated degradation process following bimolecular kinetics with rate constant $\\gamma$. This contributes a loss term $-\\gamma m(x) M(x,t)$, where $m(x)$ is the concentration of the microRNA.\n\nCombining these terms, the rate of change of the mRNA concentration at position $x$ is described by the following ordinary differential equation, as diffusion is assumed negligible:\n$$\n\\frac{dM(x,t)}{dt} = \\alpha - \\delta M(x,t) - \\gamma m(x) M(x,t)\n$$\nThis equation can be rewritten as:\n$$\n\\frac{dM}{dt} = \\alpha - (\\delta + \\gamma m(x)) M\n$$\nHere, $x$ is treated as a parameter, since we are considering the dynamics at a fixed position.\n\nThe first part of the problem requires the derivation of the steady-state mRNA concentration, denoted as $M^{*}(x)$. At steady state, the concentration does not change with time, which implies $\\frac{dM}{dt} = 0$. Setting the rate equation to zero yields:\n$$\n0 = \\alpha - (\\delta + \\gamma m(x)) M^{*}(x)\n$$\nWe can now solve this algebraic equation for $M^{*}(x)$:\n$$\n(\\delta + \\gamma m(x)) M^{*}(x) = \\alpha\n$$\n$$\nM^{*}(x) = \\frac{\\alpha}{\\delta + \\gamma m(x)}\n$$\nThe problem provides the spatial profile of the miRNA concentration as $m(x) = m_{0} \\exp(-\\lambda x)$. Substituting this expression into the equation for $M^{*}(x)$ gives the complete steady-state profile of the Hox mRNA:\n$$\nM^{*}(x) = \\frac{\\alpha}{\\delta + \\gamma m_{0} \\exp(-\\lambda x)}\n$$\nThis completes the first task. The expression shows that at large $x$, as $\\exp(-\\lambda x) \\to 0$, the mRNA concentration approaches its maximum value, $M_{max} = \\frac{\\alpha}{\\delta}$. At $x=0$, the mRNA concentration is at its minimum, $M_{min} = \\frac{\\alpha}{\\delta + \\gamma m_0}$, due to maximal repression by the miRNA.\n\nThe second part of the problem asks for the position of the anterior boundary, $x_{b}$, which is defined as the location where the steady-state mRNA concentration equals a specific threshold, $T$. Thus, we must solve the equation $M^{*}(x_{b}) = T$.\n$$\nT = \\frac{\\alpha}{\\delta + \\gamma m_{0} \\exp(-\\lambda x_{b})}\n$$\nThe problem provides the condition $\\frac{\\alpha}{\\delta} > T > \\frac{\\alpha}{\\delta + \\gamma m_{0}}$. This is equivalent to $M_{max} > T > M_{min}$. Since $M^{*}(x)$ is a continuous and monotonically increasing function of $x$ for $x \\ge 0$, this condition guarantees the existence of a unique positive solution $x_{b}$.\n\nTo find $x_{b}$, we rearrange the equation algebraically:\n$$\n\\delta + \\gamma m_{0} \\exp(-\\lambda x_{b}) = \\frac{\\alpha}{T}\n$$\nIsolate the exponential term:\n$$\n\\gamma m_{0} \\exp(-\\lambda x_{b}) = \\frac{\\alpha}{T} - \\delta\n$$\n$$\n\\exp(-\\lambda x_{b}) = \\frac{1}{\\gamma m_{0}} \\left(\\frac{\\alpha}{T} - \\delta\\right)\n$$\nTo solve for $x_{b}$, we take the natural logarithm, $\\ln$, of both sides:\n$$\n\\ln\\left(\\exp(-\\lambda x_{b})\\right) = \\ln\\left[\\frac{1}{\\gamma m_{0}} \\left(\\frac{\\alpha - \\delta T}{T}\\right)\\right]\n$$\n$$\n-\\lambda x_{b} = \\ln\\left(\\frac{\\alpha - \\delta T}{\\gamma m_{0} T}\\right)\n$$\nFinally, we solve for $x_{b}$:\n$$\nx_{b} = -\\frac{1}{\\lambda} \\ln\\left(\\frac{\\alpha - \\delta T}{\\gamma m_{0} T}\\right)\n$$\nUsing the property of logarithms, $-\\ln(z) = \\ln(1/z)$, we can invert the argument of the logarithm to eliminate the leading negative sign. This is generally preferred for clarity.\n$$\nx_{b} = \\frac{1}{\\lambda} \\ln\\left(\\left(\\frac{\\alpha - \\delta T}{\\gamma m_{0} T}\\right)^{-1}\\right)\n$$\n$$\nx_{b} = \\frac{1}{\\lambda} \\ln\\left(\\frac{\\gamma m_{0} T}{\\alpha - \\delta T}\\right)\n$$\nThis represents the final, closed-form expression for the boundary position $x_{b}$ in terms of the given parameters. The condition $T > \\frac{\\alpha}{\\delta + \\gamma m_{0}}$ ensures that the argument of the logarithm is greater than $1$, resulting in a positive value for $x_{b}$, which is physically correct.", "answer": "$$\\boxed{\\frac{1}{\\lambda} \\ln\\left(\\frac{\\gamma m_{0} T}{\\alpha - \\delta T}\\right)}$$", "id": "2644510"}, {"introduction": "Moving from single genes to the entire Hox cluster, this final practice challenges you to integrate multiple layers of regulation to predict organism-level outcomes. The linear arrangement of Hox genes on the chromosome is crucial for their coordinated expression. By analyzing a hypothetical chromosomal inversion, you will apply core concepts like colinearity, enhancer-promoter communication within Topologically Associating Domains (TADs), and posterior prevalence to forecast changes in the vertebrate body plan—a classic exercise in developmental genetics [@problem_id:2644552].", "problem": "A mouse line carries a targeted inversion of a contiguous block within the *HoxA* cluster that includes *Hoxa6*, *Hoxa7*, *Hoxa8*, *Hoxa9*, and *Hoxa10*. The inversion endpoints are engineered so that: (i) the inverted block remains inside the same Topologically Associating Domain (TAD) as the rest of the cluster; (ii) the $3'$ Global Control Region (GCR) and $3'$ Retinoic Acid (RA)-responsive enhancers are preserved and remain at the $3'$ side of the cluster; (iii) no coding sequences or core promoters are disrupted; and (iv) all CCCTC-binding factor (CTCF) boundary elements at the cluster edges are intact, although CTCF sites within the inverted block are flipped in orientation by the inversion. In the wild type, genes closer to the $3'$ end of the cluster are activated earlier and have more anterior expression boundaries than genes toward the $5'$ end, and in regions of co-expression, more $5'$ *Hox* proteins suppress anterior Hox activities (posterior prevalence). Enhancer action is predominantly orientation-insensitive and contact frequency is governed by genomic proximity and insulation within a TAD.\n\nBased on these principles, predict the most likely direction of change in the anterior expression boundaries of *Hoxa10* and *Hoxa6* in the inversion line, and the resulting axial homeotic transformations near the cervico–thoracic transition. Which option best captures the expected expression shifts and phenotype?\n\nA. *Hoxa10*’s anterior boundary shifts anteriorly, approaching the normal *Hoxa6* boundary due to its new proximity to the $3'$ GCR and RA enhancers; *Hoxa6*’s boundary shifts posteriorly. By posterior prevalence, anterior thoracic vertebrae are posteriorized, with loss of ribs and acquisition of lumbar-like features (e.g., $T_1$ lacking a rib).\n\nB. Enhancer–promoter communication is blocked by promoter orientation after inversion; genes inside the inverted block become largely silent. The resulting loss of posterior Hox function causes global anteriorization with duplicated cervical elements and an expanded ribless region throughout the thorax.\n\nC. Expression boundaries are set solely by diffusible morphogen gradients such as RA and are independent of linear genomic proximity within a TAD; therefore, neither *Hoxa10* nor *Hoxa6* shifts its anterior boundary, and axial identities remain unchanged.\n\nD. Bringing *Hoxa6* closer to the $5'$ end increases its access to global control, shifting its anterior boundary anteriorly and producing ectopic ribs on $C_7$ (posteriorization of cervical vertebrae), whereas *Hoxa10* remains restricted posteriorly due to inverted promoter orientation.", "solution": "The problem statement describes a targeted chromosomal inversion within the murine *HoxA* gene cluster and asks for a prediction of the resulting changes in gene expression and axial skeleton morphology. The problem is scientifically grounded, well-posed, and internally consistent, and therefore is valid for analysis.\n\nThe fundamental principles governing the solution are provided:\n$1$. The *Hox* cluster is regulated by enhancers, including a Global Control Region (GCR), located at its $3'$ end.\n$2$. There is a temporal and spatial collinearity in gene activation: genes are activated sequentially from the $3'$ end to the $5'$ end of the cluster. This results in genes at the $3'$ end having more anterior expression boundaries.\n$3$. Contact frequency between enhancers and promoters, which drives expression, is governed by linear genomic proximity within a Topologically Associating Domain (TAD).\n$4$. Enhancer action is stated to be predominantly orientation-insensitive.\n$5$. The principle of posterior prevalence dictates that in regions of co-expression, the function of the more posteriorly expressed ($5'$) *Hox* gene is dominant.\n\nLet us analyze the genomic rearrangement.\nIn the wild-type (WT) configuration, the gene order along the chromosome is:\n$$3' \\text{ enhancers} - ... - *Hoxa5* - *Hoxa6* - *Hoxa7* - *Hoxa8* - *Hoxa9* - *Hoxa10* - *Hoxa11* - ... - 5'$$\nIn this arrangement, *Hoxa6* is located much closer to the $3'$ regulatory elements than *Hoxa10*. Consequently, *Hoxa6* is activated earlier and is expressed more anteriorly than *Hoxa10*. The anterior boundary of *Hoxa6* expression is associated with the cervico-thoracic transition, specifying thoracic identity (e.g., rib formation on the first thoracic vertebra, $T_1$). The anterior boundary of *Hoxa10* is more posterior, delineating regions such as the lumbar vertebrae, which lack ribs.\n\nThe engineered inversion reverses the segment from *Hoxa6* to *Hoxa10*. The new genomic order is:\n$$3' \\text{ enhancers} - ... - *Hoxa5* - *Hoxa10* - *Hoxa9* - *Hoxa8* - *Hoxa7* - *Hoxa6* - *Hoxa11* - ... - 5'$$\nThe critical consequence of this inversion is the radical change in the linear distance of *Hoxa6* and *Hoxa10* from the $3'$ GCR and associated enhancers.\n- *Hoxa10* is now positioned immediately adjacent to the $3'$ part of the cluster, where *Hoxa6* was previously. Based on the principle that contact frequency is governed by genomic proximity, *Hoxa10* will now interact much more frequently with the $3'$ enhancers. This will cause its expression to be initiated earlier in development and in more anterior embryonic regions. Its anterior expression boundary is therefore predicted to shift anteriorly, towards the position normally occupied by the *Hoxa6* boundary.\n- Conversely, *Hoxa6* is now located much farther from the $3'$ enhancers, near the $5'$ end of the inverted block. Its access to the activating signals from the $3'$ GCR will be delayed and reduced. This will cause its expression to be initiated later and its anterior expression boundary to shift posteriorly.\n\nNext, we predict the phenotypic outcome based on these expression changes, focusing on the cervico-thoracic transition.\nThe anterior shift of *Hoxa10* expression means that a gene whose normal function is to specify posterior (e.g., lumbar) identity will be ectopically expressed in the anterior thorax. According to the principle of posterior prevalence, *Hoxa10* (a more $5'$, or posterior, gene in the original context) will suppress the function of the more anterior *Hox* genes with which it is now co-expressed. This results in a homeotic transformation of anterior structures to a more posterior fate. Specifically, anterior thoracic vertebrae (like $T_1$) will acquire characteristics of more posterior, lumbar vertebrae. The defining feature of lumbar vertebrae is the absence of ribs. Therefore, the expected phenotype is the loss of ribs on anterior thoracic vertebrae, a phenomenon known as posteriorization.\n\nNow, we evaluate each option based on this derivation.\n\nA. *Hoxa10*’s anterior boundary shifts anteriorly, approaching the normal *Hoxa6* boundary due to its new proximity to the $3'$ GCR and RA enhancers; *Hoxa6*’s boundary shifts posteriorly. By posterior prevalence, anterior thoracic vertebrae are posteriorized, with loss of ribs and acquisition of lumbar-like features (e.g., $T_1$ lacking a rib).\nThis statement accurately describes the predicted shifts in gene expression for both *Hoxa10* (anteriorly) and *Hoxa6* (posteriorly) based on their changed proximity to the $3'$ enhancers. It correctly applies the principle of posterior prevalence to predict the phenotypic outcome: the ectopic anterior expression of the posterior-identity gene *Hoxa10* causes a posteriorization of the anterior thorax, resulting in the loss of ribs. This aligns perfectly with our derivation.\n**Verdict: Correct**.\n\nB. Enhancer–promoter communication is blocked by promoter orientation after inversion; genes inside the inverted block become largely silent. The resulting loss of posterior Hox function causes global anteriorization with duplicated cervical elements and an expanded ribless region throughout the thorax.\nThis option posits that inverted promoters become non-functional. This contradicts the given principle that \"enhancer action is predominantly orientation-insensitive.\" While promoter orientation itself is a factor, the problem directs us to prioritize the given rules. A complete silencing is an extreme and unlikely outcome. Furthermore, the predicted phenotype of \"global anteriorization\" is what one expects from a loss-of-function, but the more direct consequence of the rearrangement is a gain-of-function of *Hoxa10* in an anterior domain, which should cause posteriorization, not anteriorization.\n**Verdict: Incorrect**.\n\nC. Expression boundaries are set solely by diffusible morphogen gradients such as RA and are independent of linear genomic proximity within a TAD; therefore, neither *Hoxa10* nor *Hoxa6* shifts its anterior boundary, and axial identities remain unchanged.\nThis option's central premise—that expression is independent of linear genomic proximity—directly contradicts a key piece of information provided in the problem statement: \"contact frequency is governed by genomic proximity\". Decades of research on *Hox* clusters have demonstrated the critical role of genomic architecture in regulating collinear expression. Therefore, the conclusion that nothing changes is based on a false premise.\n**Verdict: Incorrect**.\n\nD. Bringing *Hoxa6* closer to the $5'$ end increases its access to global control, shifting its anterior boundary anteriorly and producing ectopic ribs on $C_7$ (posteriorization of cervical vertebrae), whereas *Hoxa10* remains restricted posteriorly due to inverted promoter orientation.\nThis option contains multiple errors in reasoning. First, it incorrectly assumes that control elements are at the $5'$ end; the problem explicitly states the key enhancers (GCR, RA) are at the $3'$ side. Moving *Hoxa6* away from the $3'$ end should shift its boundary posteriorly, not anteriorly. Second, it incorrectly predicts the fate of *Hoxa10*, again invoking promoter orientation against the provided rules and ignoring the dominant effect of its new proximity to the $3'$ enhancers. While ectopic ribs on $C_7$ would be a posteriorization, the proposed mechanism for the underlying gene expression change is flawed.\n**Verdict: Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "2644552"}]}